This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Data to support the findings of this research can be made available by the corresponding author upon reasonable request.
Kuehn BM. The Promise and Challenges of CAR-T Gene Therapy. JAMA. 2017;318:2167–9.
Treatment Centers Authorized to Administer CAR T Cell Therapy—The ASCO Post [Internet]. [cited 2021 Nov 28]. Available from: https://ascopost.com/issues/may-25-2018/treatment-centers-authorized-to-administer-car-t-cell-therapy/.
Mian A, Wei W, Winter AM, Khouri J, Jagadeesh D, Anwer F, et al. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. Leuk Lymphoma. 2021;62:1344–52.
Nastoupil LJ, Jain MD, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience. Blood. 2018;132:91.
Azoulay E, Shimabukuro-Vornhagen A, Darmon M, von Bergwelt-Baildon M. Critical care management of chimeric antigen receptor T cell-related toxicity. be aware and prepared. Am J Respir Crit Care Med. 2019;200:20–3.
Bach PB. National coverage analysis of CAR-T therapies—policy, evidence, and payment. N Engl J Med. 2018;379:1396–8.
Kilgore KM, Mohammadi I, Schroeder A, Teigland C, Purdum AG, Shah GL. Medicare patients receiving chimeric antigen receptor T-cell therapy for Non-Hodgkin lymphoma: a real-world look at patient characteristics, healthcare utilization and costs. Biol Blood Marrow Transpl. 2020;26:S43–4.
Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma. JAMA Netw Open. 2020;3:e202072.
Shah GL, Park J, Sauter CS, Duck E, Halton E, Batlevi CW. et al. Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies. Biol Blood Marrow Transpl. 2019;25 Suppl 3:S38–9.
Brown ART, Jindani I, Melancon J, Erfe R, Westin J, Feng L, et al. ICU resource use in critically III patients following chimeric antigen receptor T-cell therapy. Am J Respir Crit Care Med. 2020;202:1184–7.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625–38.
Ballen KK, Joffe S, Brazauskas R, Wang Z, Aljurf MD, Akpek G, et al. Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources. Biol Blood Marrow Transpl. 2014;20:1819–27.
Harris AH, Hohmann S, Shippey E, Epting G. Quality and cost outcomes in chimeric antigen receptor T-cell immunotherapy in adult large B-Cell cancer patients from the vizient clinical database. Biol Blood Marrow Transpl. 2020;26 Suppl 3:S316–7.
Riedell PA, Walling C, Nastoupil LJ, Pennisi M, Maziarz RT, McGuirk JP, et al. A multicenter retrospective analysis of outcomes and toxicities with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas. Biol Blood Marrow Transpl. 2020;26:S41–2.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.
Chakraborty R, Hill BT, Majeed A, Majhail NS. Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies. Transpl Cell Ther. 2021;27:222–9.
NSM serves as a consultant for Anthem, Inc. BTH and PFC have received research funding and consulting feeds from Kite/Gilead and Novartis. AM received funding from ASH HONORS Grant for year 2022–2023.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mian, A., Wei, W., Hamilton, B.K. et al. Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel. Bone Marrow Transplant 58, 590–593 (2023). https://doi.org/10.1038/s41409-023-01934-4